Want to see BIOX full AI Analyst Report?
Bioceres Crop Solutions (BIOX) AI Stock Analysis
Bioceres Crop Solutions
(NASDAQ:BIOX)
The score is held down primarily by sharply weakened profitability and elevated leverage, reinforced by an earnings-call backdrop of falling revenues, negative EBITDA, litigation/debt-acceleration risk and limited liquidity. Offsetting factors are improved operating/free cash flow and some near-term technical stabilization, but the longer-term trend and loss-making profile remain key constraints.
Bioceres Crop Solutions Key Performance Indicators (KPIs)
Revenue by SegmentShows how much revenue each business segment contributes, highlighting areas of strength and potential growth within Bioceres Crop Solutions' diverse operations.
Bioceres’ revenue base has weakened from its 2023–24 highs, with Crop Protection driving most of the decline and Seed and Integrated Products contracting even more sharply. Crop Nutrition, once a meaningful growth engine, has also settled at substantially lower levels but appears comparatively stable recently. The mix therefore remains heavily dependent on Crop Protection, while newer or adjacent businesses are not yet providing enough scale to offset softer demand and likely heightened agricultural-market volatility.
The FlyBioceres Crop Solutions (BIOX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $13.15M
- Dividend Yield
- ―
- Average Volume (3M)
- 313.18K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.38
- Revenue Growth
- -26.10%
- EPS Growth
- 14.85%
- Country
- US
- Employees
- 751
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Agricultural Inputs
Bioceres Crop Solutions Business Overview & Revenue Model
Company Description
Bioceres Crop Solutions Corp. (BIOX) is a company dedicated to enhancing agricultural output through a diverse range of solutions. Its operations are organized into three principal divisions. The Seed and Integrated Products segment is responsible fo...
How the Company Makes Money
Bioceres Crop Solutions makes money by selling agricultural input products and related technologies to growers and channel partners (e.g., distributors, retailers, and seed companies). Its revenue model is primarily product-based, with key revenue st...
Bioceres Crop Solutions Earnings Call Summary
The call reflected a mixed outlook. Management highlighted fourth-quarter revenue stabilization, positive adjusted EBITDA, substantial cost reductions, improved performance in several core product categories, and progress on debt maturity management and strategic simplification. However, fiscal-year revenue, gross profit, margins, and adjusted EBITDA declined, while creditor litigation, high net financial debt, inventory obsolescence, and weakness in parts of the Seeds, Crop Protection, and inoculant businesses remained significant challenges.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal year 2027 and beyond, Bioceres is targeting about 40% gross margins by focusing growth on higher quality core revenue streams particularly in Brazil and simplifying the product portfolio to focus on the most valuable and value accretive SKUs; it is also targeting a combined 23% total SG&A as a percent of revenues for fiscal year 2028, while continuing to explore further efficiencies on the OpEx front and noncore asset monetization opportunities, maintaining cost and working capital discipline, and actively addressing the company's capital structure and liquidity position.
Bioceres Crop Solutions Financial Statement Overview
Summary
Overall fundamentals are weak: the income statement has deteriorated sharply with declining TTM revenue (-10.4%) and very large losses (net margin ~-82.8%), while the balance sheet shows materially higher leverage (TTM debt-to-equity ~3.25x) and reduced flexibility. The main offset is improved cash generation with strong TTM operating cash flow (~$78M) and free cash flow (~$72M), though debt coverage remains thin (OCF coverage ~0.24).
Income Statement
22NegativeBalance Sheet
33NegativeCash Flow
58Neutral| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 263.68M | 333.34M | 464.83M | 419.45M | 328.46M | 206.70M |
| Gross Profit | 96.80M | 128.15M | 181.59M | 180.25M | 126.44M | 90.88M |
| EBITDA | -20.12M | -9.76M | 55.46M | 72.38M | 47.91M | 43.70M |
| Net Income | -250.55M | -55.42M | 3.24M | 18.78M | -7.20M | -6.87M |
Balance Sheet | ||||||
| Total Assets | 529.60M | 763.65M | 852.55M | 818.06M | 518.22M | 394.59M |
| Cash, Cash Equivalents and Short-Term Investments | 14.90M | 34.74M | 56.17M | 60.05M | 38.61M | 46.78M |
| Total Debt | 240.00M | 276.61M | 270.95M | 257.41M | 169.79M | 174.58M |
| Total Liabilities | 439.70M | 468.43M | 501.17M | 487.56M | 359.92M | 304.30M |
| Stockholders Equity | 63.80M | 262.81M | 315.30M | 298.85M | 127.61M | 67.74M |
Cash Flow | ||||||
| Free Cash Flow | 54.77M | 35.30M | 18.93M | -19.97M | -26.51M | -20.13M |
| Operating Cash Flow | 58.53M | 49.91M | 41.72M | 2.59M | -17.52M | -6.21M |
| Investing Cash Flow | -2.58M | -6.13M | -28.73M | -25.73M | 2.90M | -8.31M |
| Financing Cash Flow | -72.41M | -50.71M | -10.06M | 32.95M | 14.82M | 7.36M |
Bioceres Crop Solutions Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOX, the sentiment is Negative. The current price of 0.21 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.35, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 30.97 is Neutral, neither overbought nor oversold. The STOCH value of 38.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOX.
Bioceres Crop Solutions Risk Analysis
Bioceres Crop Solutions disclosed 68 risk factors in its most recent earnings report. Bioceres Crop Solutions reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBioceres Crop Solutions Peers Comparison
Overall Rating
CTVA69Neutral
SEED47Neutral
AVD44Neutral- BIOX43Neutral
FMC42Neutral
RKDA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CTVA | 69Neutral | $7.77B | 51.28 | 4.08% | 0.93% | 3.70% | -26.39% |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| SEED | 47Neutral | $10.95M | -0.83 | 88.44% | ― | -25.50% | -905.27% |
| AVD | 44Neutral | $32.45M | -0.58 | -27.83% | ― | -3.54% | 56.67% |
| BIOX | 43Neutral | $13.15M | -0.06 | -216.09% | ― | -26.10% | 14.85% |
| FMC | 42Neutral | $964.39M | -0.19 | -308.88% | 5.16% | -21.99% | -677.23% |
| RKDA | 39Underperform | $380.41K | -0.02 | -339.85% | ― | -12.24% | 17.56% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BIOX | Bioceres Crop Solutions | 0.21 | -1.65 | -88.82% | |
| AVD | American Vanguard Corporation | 1.10 | -3.57 | -76.45% | |
| FMC | FMC Corp | 6.20 | -7.62 | -55.14% | |
| SEED | Origin Agritech | 0.77 | -0.88 | -53.09% | |
| RKDA | Arcadia Biosciences Inc. | 0.16 | -3.45 | -95.65% | |
| CTVA | Corteva | 11.64 | 2.42 | 26.19% |
Bioceres Crop Solutions Corporate Events
Bioceres Crop Solutions Revises Q3 Results and Faces Adverse Court Ruling in Noteholder Dispute
Bioceres Crop Solutions updated its fiscal third-quarter 2026 results on June 19 after recording an additional provision of about $3.4 million under IAS 37 tied to contingent payments from past acquisitions, an adjustment that did not affect revenue,...
Bioceres Subsidiary Rizobacter Completes US$42.7 Million Note Exchange to Extend Debt Maturities
On May 29, 2026, Rizobacter Argentina, a subsidiary of Bioceres Crop Solutions, announced it had successfully completed an exchange offer and consent solicitation for several series of its outstanding notes. The offer secured participation from holde...
Bioceres Crop Solutions Posts 3Q 2026 Loss as Revenues Slide During Post–Pro Farm Restructuring
Bioceres Crop Solutions reported fiscal third-quarter 2026 results on May 11, 2026, with revenues from continuing operations falling 23% year over year to $39.4 million and gross profit down 30% to $12.7 million. The company posted a net loss of $10....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 12, 2026